How do IgG IgM rapid tests work in China?

Table of Contents

1. Introduction
2. Principles of IgG IgM Rapid Tests
3. Application in China
4. Immuno Company Solutions
5. Numerical Analysis
6. Conclusion
7. References

Introduction

The COVID-19 pandemic accelerated the need for rapid testing solutions around the world. One popular method is the IgG/IgM rapid test, particularly in China, where quick, reliable testing is critical for controlling outbreaks. This article details how these tests work and their implementation strategies within China. Additionally, solutions from the Immuno Company are examined.

Principles of IgG IgM Rapid Tests

IgG and IgM rapid tests are immunoassays designed to detect antibodies to SARS-CoV-2 in human blood, serum, or plasma. The test detects two types of antibodies: Immunoglobulin M (IgM), usually the first antibody produced by the immune response, and Immunoglobulin G (IgG), which appears later. The presence of IgM antibodies indicates recent infection, while IgG suggests a later stage or past infection.

Application in China

In China, these rapid tests are used extensively for mass screening, occupational health, and follow-up testing. Due to the strategic implementation and availability of rapid tests, authorities can quickly quarantine individuals and prevent widespread transmission. The sensitivity and specificity metrics reported in Chinese studies are often cited above 90% and 95% respectively.

Immuno Company Solutions

Immuno Company has pioneered several solutions to enhance the efficacy and distribution of IgG/IgM rapid tests in China. These involve:

• Developing multi-antigen tests to increase specificity.
• Using AI algorithms to assist in the interpretation of test results.
• Implementing blockchain for secure data management and result authentication.

Numerical Analysis

The performance of IgG/IgM rapid tests is quantified in terms of sensitivity, specificity, and throughput:

• Sensitivity: The probability of a positive test among infected individuals. Chinese IgG/IgM tests show sensitivity rates as high as 96% in controlled environments.
• Specificity: The probability of a negative test among non-infected individuals. Reports suggest specificity metrics often exceeding 98% in official Chinese testing campaigns.
• Throughput: The number of tests processed per hour. Enhancements in manufacturing and processing have resulted in approximately 10,000 tests per hour per facility in state-operated labs.

Conclusion

The implementation of IgG/IgM rapid tests in China showcases an effective model for large-scale health surveillance. With ongoing innovations by companies like Immuno, the efficiency and reliability of these tests continue to improve, ensuring better health outcomes.

References

1. World Health Organization. Antibody Detection Tests for COVID-19. WHO, 2023.
2. Zhao, J. et al., Antibody Responses to SARS-CoV-2 in Patients and the Community, Nature Medicine, 2022.
3. Immuno Company Report. Advancements in Rapid Testing, Immuno Corp, 2023.